Distinct patterns of SARS-CoV-2 viral dynamics in saliva reveal heterogeneity that cannot be sufficiently explained by conventional clinical characteristics or microRNA profiles alone.
Generated Record Revenue and 5% Positive Operating Leverage Increases Planned Share Repurchases Fourth Quarter 2025 net income was $2.0 Billion, $4.88 Diluted EPS Grew NII, NIM and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback